Published in J Clin Oncol on January 21, 2014
Methylation Analysis of Circulating Tumor DNA in Gastric Cancer | NCT04511559
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med (2015) 2.65
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature (2017) 2.54
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol (2014) 2.23
Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell (2016) 2.03
Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet (2016) 1.50
Filtration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer. PLoS One (2015) 1.39
Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol (2016) 1.32
Next-generation sequencing to guide cancer therapy. Genome Med (2015) 1.31
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res (2015) 1.29
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clin Cancer Res (2015) 1.29
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol (2014) 1.26
Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med (2014) 1.24
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol (2015) 1.22
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep (2014) 1.22
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One (2015) 1.15
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer (2014) 1.14
Translational implications of tumor heterogeneity. Clin Cancer Res (2015) 1.12
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov (2015) 1.07
Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci U S A (2016) 1.06
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget (2016) 1.03
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget (2015) 1.02
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr Opin Genet Dev (2014) 1.01
Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer (2015) 1.01
Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform. Int J Mol Sci (2015) 1.01
Circulating tumor-derived DNA is shorter than somatic DNA in plasma. Proc Natl Acad Sci U S A (2015) 0.99
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep (2015) 0.96
Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics (2015) 0.96
Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. J Clin Oncol (2016) 0.94
Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol (2017) 0.94
Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. Blood (2016) 0.94
Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget (2015) 0.93
Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med (2015) 0.93
Circulating DNA as biomarker in breast cancer. Breast Cancer Res (2015) 0.93
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer (2015) 0.92
Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer. Springerplus (2015) 0.91
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) (2014) 0.91
The multitude of molecular analyses in cancer: the opening of Pandora’s box. Genome Biol (2014) 0.90
Circulating Cell-Free Tumour DNA in the Management of Cancer. Int J Mol Sci (2015) 0.90
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. Transl Lung Cancer Res (2015) 0.89
Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment. Cancer Sci (2016) 0.89
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun (2016) 0.89
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clin Gastroenterol Hepatol (2016) 0.88
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers†. Ann Oncol (2015) 0.87
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. J Hematol Oncol (2016) 0.86
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol (2014) 0.86
Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol (2015) 0.85
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer. PLoS One (2014) 0.85
Pros: Can tissue biopsy be replaced by liquid biopsy? Transl Lung Cancer Res (2016) 0.85
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget (2016) 0.85
Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer. Oncotarget (2016) 0.85
Cell-free circulating tumor DNA in cancer. Chin J Cancer (2016) 0.85
Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? Expert Rev Mol Diagn (2015) 0.84
Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget (2015) 0.84
Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities. Genome Med (2016) 0.83
Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology. Transl Oncol (2015) 0.83
Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing. PLoS One (2016) 0.83
Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl Lung Cancer Res (2015) 0.83
Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease. Springerplus (2016) 0.83
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. PLoS Med (2016) 0.83
Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer. Oncologist (2016) 0.83
Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure. Cancer Sci (2016) 0.83
Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget (2016) 0.83
Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions. Mol Oncol (2017) 0.83
Cancer immunoprevention--the next frontier. Cancer Prev Res (Phila) (2014) 0.82
Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients. Sci Rep (2016) 0.82
Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica (2015) 0.82
BRAF Mutations in Canine Cancers. PLoS One (2015) 0.82
Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. Physiol Genomics (2014) 0.82
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol (2016) 0.82
The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencing. Sci Rep (2016) 0.82
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther Adv Med Oncol (2017) 0.81
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget (2016) 0.81
Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer (2016) 0.81
DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. Asian J Androl (2016) 0.81
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen. Oncotarget (2016) 0.81
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. Chin J Cancer (2015) 0.81
Liquid biopsy in gastrointestinal stromal tumors: a novel approach. J Transl Med (2014) 0.81
The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Cancer Gene Ther (2015) 0.81
Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. Cancer Sci (2015) 0.80
Circulating glioma biomarkers. Neuro Oncol (2014) 0.80
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget (2016) 0.80
Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget (2016) 0.80
Treatment of metastatic colorectal cancer: focus on panitumumab. Cancer Manag Res (2015) 0.80
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nat Commun (2016) 0.80
Pharmacologic biomarkers in the development of stratified cancer medicine. Clin Cancer Res (2014) 0.80
Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget (2016) 0.79
Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer. Expert Rev Mol Diagn (2015) 0.79
The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget (2015) 0.79
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions. Front Oncol (2015) 0.79
Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing. Nucleic Acids Res (2016) 0.79
The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol (2015) 0.79
Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel. PLoS One (2016) 0.79
Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco Targets Ther (2016) 0.79
Precision Oncology Framework for Investigation of Exercise As Treatment for Cancer. J Clin Oncol (2015) 0.79
Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica (2016) 0.79
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. Oncologist (2016) 0.79
Emerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers. Clin Cancer Res (2017) 0.79
Liquid Biopsies for Cancer: Coming to a Patient near You. J Clin Med (2017) 0.78
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Cancer genome landscapes. Science (2013) 25.33
Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (1980) 17.69
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res (1989) 15.35
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Digital PCR. Proc Natl Acad Sci U S A (1999) 10.54
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Presence of fetal DNA in maternal plasma and serum. Lancet (1997) 9.01
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A (2008) 8.38
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol (2009) 6.43
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 5.45
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature (2010) 4.53
Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med (1998) 4.29
Digital karyotyping. Proc Natl Acad Sci U S A (2002) 3.96
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res (2006) 3.66
Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem (2012) 3.35
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
[Not Available]. C R Seances Soc Biol Fil (1948) 3.32
BEAMing up for detection and quantification of rare sequence variants. Nat Methods (2006) 3.03
Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem (2004) 2.79
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res (2006) 2.68
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem (2013) 2.45
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res (2009) 2.35
Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol (2009) 2.34
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res (2012) 2.25
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res (2011) 2.23
Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med (2011) 2.19
About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta (2001) 2.18
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 2.07
The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70
PCR-based methods for the enrichment of minority alleles and mutations. Clin Chem (2009) 1.65
Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res (2009) 1.50
Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst (2009) 1.48
High fragmentation characterizes tumour-derived circulating DNA. PLoS One (2011) 1.42
Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin Chim Acta (2003) 1.34
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol (2006) 1.20
Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res (2010) 1.17
Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci (2008) 1.17
Genomic analysis of fetal nucleic acids in maternal blood. Annu Rev Genomics Hum Genet (2012) 1.15
The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke. Clin Chim Acta (2010) 1.11
Pyrophosphorolysis-activated polymerization (PAP): application to allele-specific amplification. Biotechniques (2000) 1.09
Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann N Y Acad Sci (2006) 1.07
Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer (2007) 1.06
Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury. Clin Chim Acta (2012) 1.06
Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients. Acute Card Care (2010) 1.04
Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest (2006) 1.02
Cell-free plasma DNA during peritoneal dialysis and hemodialysis and in patients with chronic kidney disease. Ann N Y Acad Sci (2008) 1.02
Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol (2012) 0.99
Disappearance curves for tumor markers after resection of intrathoracic malignancies. Int J Biol Markers (1999) 0.98
Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal (2012) 0.98
Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett (2012) 0.98
Apoptotic cell-free DNA promotes inflammation in haemodialysis patients. Nephrol Dial Transplant (2011) 0.97
Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One (2012) 0.97
Circulating cell-free DNA in hemodialysis patients predicts mortality. Nephrol Dial Transplant (2012) 0.95
Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma. Jpn J Clin Oncol (2002) 0.95
Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples. Clin Med Insights Pathol (2012) 0.94
Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw (2013) 0.93
Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Mol Biosyst (2011) 0.92
Cell-free DNA as a marker for prediction of brain damage in traumatic brain injury in rats. J Neurotrauma (2011) 0.92
Cell-free DNA levels in acute myocardial infarction patients during hospitalization. Acta Cardiol (2009) 0.92
Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR. Clin Chem Lab Med (2006) 0.91
Short-term treadmill running as a model for studying cell-free DNA kinetics in vivo. Clin Chem (2011) 0.89
Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. Anticancer Res (2012) 0.89
A sensitive method to quantify human cell-free circulating DNA in blood: relevance to myocardial infarction screening. Clin Biochem (2011) 0.87
Single-tube analysis of DNA methylation with silica superparamagnetic beads. Clin Chem (2010) 0.87
Enzymatic incorporation of multiple dyes for increased sensitivity in QD-FRET sensing for DNA methylation detection. Chembiochem (2010) 0.87
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
International network of cancer genome projects. Nature (2010) 20.35
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res (2013) 2.61
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res (2007) 1.98
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol (2010) 1.80
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med (2014) 1.79
Identifying tumor origin using a gene expression-based classification map. Cancer Res (2003) 1.78
Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res (2004) 1.68
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res (2012) 1.51
PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res (2005) 1.43
Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. Hum Mutat (2013) 1.42
Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 1.38
Targeted therapies: how personal should we go? Nat Rev Clin Oncol (2011) 1.31
PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat (2008) 1.29
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer (2013) 1.26
SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. Proc Natl Acad Sci U S A (2004) 1.20
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A (2011) 1.16
MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat (2010) 1.13
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med (2015) 1.12
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer (2010) 1.04
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res (2008) 1.02
Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Cancer Res (2007) 1.01
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res (2011) 1.00
Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica (2010) 1.00
The road to resistance: EGFR mutation and cetuximab. Nat Med (2012) 0.98
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. PLoS One (2012) 0.98
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. Hum Mutat (2009) 0.97
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res (2010) 0.97
Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci U S A (2007) 0.95
Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. Hum Mutat (2009) 0.92
Isogenic mutant human cells: a new tool for personalized cancer medicine. Cell Cycle (2010) 0.90
Expression and functional regulation of myoglobin in epithelial cancers. Am J Pathol (2009) 0.90
PRL-3: a phosphatase for metastasis? Cancer Biol Ther (2004) 0.89
KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PLoS One (2011) 0.89
Genomic landscapes of cancers: prospects for targeted therapies. Pharmacogenomics (2007) 0.87
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol (2014) 0.86
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Target Oncol (2010) 0.86
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leuk Lymphoma (2011) 0.85
Mutational profiling of kinases in glioblastoma. BMC Cancer (2014) 0.84
Absence of AKT1 mutations in glioblastoma. PLoS One (2009) 0.83
Somatic alterations as the basis for resistance to targeted therapies. J Pathol (2014) 0.83
BRAF V600E is a determinant of sensitivity to proteasome inhibitors. Mol Cancer Ther (2013) 0.82
Climbing RAS, the everest of oncogenes. Cancer Discov (2014) 0.81
Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. Cancer Res (2013) 0.81
Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells. Mol Cancer Ther (2005) 0.81
Kinase mutations in cancer: chinks in the enemy's armour? Curr Opin Oncol (2006) 0.79
Activation of β-catenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response. PLoS One (2012) 0.79
Identification of cancer genes by mutational profiling of tumor genomes. FEBS Lett (2005) 0.78
Broccoli, PTEN deletion and prostate cancer: where is the link? Mol Cancer (2010) 0.77
Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells. Cancer Res (2007) 0.77
Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. PLoS One (2010) 0.77
Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D). Biochem Biophys Res Commun (2009) 0.77
Understanding how kinase-targeted therapies work. Cell Cycle (2008) 0.77
Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing? Clin Cancer Res (2013) 0.76
Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? Cell Mol Life Sci (2013) 0.76
Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells. Hum Mutat (2013) 0.76
Tracking the genomic evolution of breast cancer metastasis. Breast Cancer Res (2010) 0.75
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS One (2017) 0.75
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS One (2016) 0.75
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. Curr Opin Mol Ther (2010) 0.75